CA2216138A1 - Composition therapeutique destinee a traiter l'arthrite - Google Patents

Composition therapeutique destinee a traiter l'arthrite Download PDF

Info

Publication number
CA2216138A1
CA2216138A1 CA002216138A CA2216138A CA2216138A1 CA 2216138 A1 CA2216138 A1 CA 2216138A1 CA 002216138 A CA002216138 A CA 002216138A CA 2216138 A CA2216138 A CA 2216138A CA 2216138 A1 CA2216138 A1 CA 2216138A1
Authority
CA
Canada
Prior art keywords
phenyl
pyrazol
benzenesulfonamide
pharmaceutical composition
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002216138A
Other languages
English (en)
Inventor
Haruhiko Makino
Takashi Sohda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2216138A1 publication Critical patent/CA2216138A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à un produit pharmaceutique, à action rapide et à effet analgésique anti-inflammatoire prolongé, utilisé dans le traitement de l'arthrite chronique, et dont les effets secondaires sont de faible prévalence. Le produit pharmaceutique de l'invention est une combinaison d'un agent thérapeutique, d'un agent prophylactique de la famille de la quinazoline et de la quinoline, utilisé dans le traitement de l'arthrite, et d'analgésiques à action anti-inflammatoire rapide comprenant (1) un inhibiteur de la cyclooxygénase, (2) un analgésique central, (3) un stéroïde ou (4) un agent enzymatique anti-inflammatoire. Ce produit pharmaceutique a un excellent effet dans le traitement de l'arthrite dès la première période d'administration, favorisant une action analgésique anti-inflammatoire stable, et dont les effets secondaires sont de faible prévalence, même dans le cas d'une administration prolongée, à condition que le choix de la combinaison du médicament, du procédé d'administration et du dosage soit fait correctement en fonction des symptômes.
CA002216138A 1995-04-28 1996-04-24 Composition therapeutique destinee a traiter l'arthrite Abandoned CA2216138A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP7/106316 1995-04-28
JP10631695 1995-04-28
JP7/270856 1995-10-19
JP27085695 1995-10-19

Publications (1)

Publication Number Publication Date
CA2216138A1 true CA2216138A1 (fr) 1996-10-31

Family

ID=26446436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216138A Abandoned CA2216138A1 (fr) 1995-04-28 1996-04-24 Composition therapeutique destinee a traiter l'arthrite

Country Status (7)

Country Link
EP (1) EP0830133A1 (fr)
KR (1) KR19990008148A (fr)
AU (1) AU715358B2 (fr)
CA (1) CA2216138A1 (fr)
HU (1) HUP9801628A2 (fr)
NO (1) NO974956D0 (fr)
WO (1) WO1996033717A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
EP0977989A1 (fr) * 1997-02-04 2000-02-09 Trega Biosciences, Inc. Derives de la quinoline substituee en 4- et bibliotheques combinatoires les contenant
EP1313707B1 (fr) 2000-08-09 2007-07-18 F. Hoffmann-La Roche Ag Derives quinoline utiles en tant qu'agents anti-inflammatoires
WO2002051442A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0339435B1 (fr) * 1988-04-26 1993-08-18 Asahi Glass Company Ltd. Composition d'un prépolymère, son procédé de préparation et son utilisation
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
TW232013B (fr) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them

Also Published As

Publication number Publication date
NO974956L (no) 1997-10-27
KR19990008148A (ko) 1999-01-25
AU715358B2 (en) 2000-01-20
NO974956D0 (no) 1997-10-27
AU5513696A (en) 1996-11-18
EP0830133A1 (fr) 1998-03-25
HUP9801628A2 (hu) 1999-01-28
WO1996033717A1 (fr) 1996-10-31

Similar Documents

Publication Publication Date Title
US20030220374A1 (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
JP4511792B2 (ja) Ｃｏｘ−２阻害剤を含む再構成可能な非経口組成物
BG103803A (bg) Метод за приложение на инхибитори на циклооксигеназа-2 при предотвратяване на смущения в сърдечно-съдовата система
JP2002538078A (ja) 痛みを治療するｎｍｄａ−ブロッカーと組み合わされたｃｏｘ−２阻害剤
WO1998050075A1 (fr) Inhibiteurs de cox-2 en combinaison avec des agents bloquants le nmda pour traiter la douleur
AU2003207535A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030157061A1 (en) Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
AU5873000A (en) Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
MXPA04001464A (es) Terapia de combinacion para el tratamiento del cancer.
CA2435835A1 (fr) Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
US20030114416A1 (en) Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
KR20070059154A (ko) 비수계의 액상 비경구 아세클로페낙 제제
US20040122011A1 (en) Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2018187698A2 (fr) Polythérapies utilisant des agents anticancéreux dépendant de la caspase-1 et des antagonistes de pge2
WO2003015797A1 (fr) Compositions assurant le traitement et la prevention de douleurs et d'inflammations a l'aide d'un inhibiteur selectif de cyclooxygenase-2 et de glucosamine
CA2216138A1 (fr) Composition therapeutique destinee a traiter l'arthrite
US20030207846A1 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
JPH09169646A (ja) 関節炎治療剤
AU758983B2 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
CA2576544A1 (fr) Composes de pyrazolone utiles pour le traitement de troubles vasculaires cerebraux associes a l'accident ischemique cerebral
JP2003081830A (ja) 酸化ストレス抑制剤
TW200528095A (en) Therapeutic combinations
AU2012331125A1 (en) 2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases
CZ9903642A3 (cs) Použití inhibitorů cyklooxygenasy-2 pro prevenci kardiovaskulárních onemocnění

Legal Events

Date Code Title Description
FZDE Discontinued